TX-SNOW-SOFTWARE
Snow Software, the global leader in technology intelligence, today announced new and enhanced capabilities to support IT leaders seeking to negotiate better contract terms, lower operating expenses and boost organizational-wide efficiencies during this period of macroeconomic uncertainty. The latest features offer a richer view of an organization’s IT investments and the impact to the business, providing new ways to optimize costs and ensure value of complex technologies like containers and cloud services. Container visibility, one of the newest innovations on the Snow Atlas platform, provides details on applications running in Kubernetes containers to identify cost savings.
“The macroeconomic environment is forcing organizations to seek a deeper understanding of how all areas of their business are performing,” said Sanjay Castelino, Chief Product and Customer Officer at Snow. “With large annual budgets devoted to IT spend, demonstrating return on investment for every technology purchase is vital for CIOs and IT teams. The latest release from Snow not only identifies how technology is used but also offers use cases to support more sustainable IT practices such as understanding the carbon footprint of devices. With IT environments more complex than ever, the intelligence Snow provides serves as the backbone for organizations seeking to get more control over IT spending and risk.”
Gaining Visibility of Container Environments
More than 70% of global organizations will use containerized applications by 2023, according to industry analysts. Widespread use of containers creates new barriers for organizations seeking to understand what is running in a container – let alone control costs.
The new container visibility feature available on Snow Atlas is designed to provide IT teams and IT asset managers (ITAM) details on what applications are running, how many containers are used in their environment, and how long containers have been running. In this release, the capability provides insights into Microsoft, Oracle and Red Hat standard containerized applications running in Kubernetes environments. Container visibility is available for Kubernetes environments running on major cloud services such as Amazon Web Services (AWS) and Microsoft Azure environments. This insight enables IT and ITAM teams to manage cost more efficiently.
Snow is inviting organizations with Kubernetes environments to use the functionality, with general availability of the capability aimed at early 2023.
Empowering ITAM to Partner with FinOps to Manage Rising Cloud Costs
To give a more complete picture of the end-to-end organizational tech stack, the latest release from Snow gives ITAM teams a spend snapshot across AWS and Azure in the terminology and views used by ITAM. With this new service – available to all Snow Atlas customers – ITAM teams have improved views of their organization’s spend profile in public cloud natively within their SAM tool. By building this feature natively within the existing SAM product, Snow makes it easier for ITAM to drive conversations about spend optimization with cloud stakeholders and FinOps teams.
For organizations with more mature cloud practices, FinOps or cloud operations practitioners, Snow Cloud Cost powered by Anodot provides greater depth of visibility, insights and analysis on public cloud spend, controls for budget management and spend allocation, detection of anomalies and recommendations for optimizing spend.
Enabling IT to Build a Sustainable Enterprise
Developing a more sustainable enterprise is a top priority for most CIOs. Snow makes it easier for IT teams to deliver on their sustainability goals. Organizations can leverage existing ITAM data, such as the laptop and desktop details, to assess their sustainability baseline. This sustainability intelligence report from Snow also includes curated information on how many certified sustainable devices exist, the spectrum of energy efficient devices and an evaluation of carbon emission reduction with on-premises to cloud shifts. The data provided by Snow enables CIOs and IT leaders to take proactive measures to actively manage and advance their sustainability initiatives.
Expanded Support to Reduce S/4HANA Migration Risks
With the end of maintenance for Business Suite 7 approaching, the migration to S/4HANA is a strategic imperative for many organizations. Snow is releasing new license intelligence, contract management and management dashboards for Snow Optimizer for SAP® Software to help offer further support with S/4HANA migrations. The new license intelligence capabilities allow organizations to easily simulate alternative license scenarios for both usage and authorization-based licensing, helping them decide on the most efficient and cost-effective migration strategy. In addition, new functionality allows for more transparent and secure management of an organization’s SAP environment by providing insight into license metrics and enhanced controls over contract management.
These new and enhanced capabilities follow several notable product milestones for Snow this year, including a new host of capabilities for Snow Atlas, a new partnership with Anodot to transform cloud cost management, verification on Oracle Database and Database Options and new enhancements for Snow Commander.
For more information or to request a demo, please visit www.snowsoftware.com.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
